A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round

Months after Bay Area startup Attralus tapped Mark Timney to its helm, the ex-Purdue Pharma chief has led the company to a $116 million Series B round — and with it, activist investor Alex Denner is joining the board.

Timney says he’ll use the funds to push Attralus’ pan-amyloid...

Click to view original post